Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-09-12FDA Approved: VIGABATRIN — Supplemental Application (Novadoz Pharmaceuticals LLC)
FDA approved a supplemental application for Vigabatrin by Novadoz Pharmaceuticals LLC. This action represents regulatory approval of an upda…
-
FDA approval · 2024-09-12FDA Approved: VIGABATRIN — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for Vigabatrin by Ascend Laboratories, LLC. The approval updates the regulatory status for Vigabatri…
-
FDA approval · 2024-09-12FDA Approved: VIGABATRIN — Supplemental Application (Carnegie Pharmaceuticals LLC)
FDA approved a supplemental application for Vigabatrin filed by Carnegie Pharmaceuticals LLC.
-
FDA approval · 2024-09-12FDA Approved: VIGABATRIN — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application to add Aurobindo Pharma Limited as an approved manufacturer of Vigabatrin.
-
FDA approval · 2024-09-12FDA Approved: SABRIL — Supplemental Application (Lundbeck Pharmaceuticals LLC)
FDA approved a supplemental application for Sabril (vigabatrin) submitted by Lundbeck Pharmaceuticals LLC. The approval updates the product …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-09-12FDA Approved: VIGABATRIN — Supplemental Application (Dr. Reddys Laboratories Inc.,)
FDA approved a supplemental application for Vigabatrin from Dr. Reddy's Laboratories Inc. (ANDA 211481).
-
FDA approval · 2024-09-12FDA Approved: VIGABATRIN — Supplemental Application (Amneal Pharmaceuticals NY LLC)
The FDA approved a supplemental application for Vigabatrin from Amneal Pharmaceuticals NY LLC to market a generic Vigabatrin product.
-
FDA approval · 2024-09-12FDA Approved: VIGABATRIN — Supplemental Application (Actavis Pharma, Inc.)
FDA approved Actavis Pharma, Inc.'s supplemental application for Vigabatrin (ANDA 209822).
-
FDA approval · 2024-09-12FDA Approved: VIGADRONE — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for VIGADRONE (vigabatrin) by Upsher-Smith Laboratories, LLC under ANDA 210196.
-
FDA approval · 2024-09-12FDA Approved: VIGABATRIN — Supplemental Application (Cipla USA, Inc.)
FDA approves a supplemental application for vigabatrin submitted by Cipla USA, Inc. The approval updates the drug's labeling and/or indicati…
-
FDA approval · 2024-09-12FDA Approved: VIGABATRIN — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Vigabatrin from Aurobindo Pharma Limited under an ANDA, granting approval for a generic form of …
-
FDA approval · 2024-09-12FDA Approved: VIGADRONE — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for Vigadrone (vigabatrin) from Upsher-Smith Laboratories, confirming an approved supplement to …
-
FDA approval · 2024-09-10FDA Approved: TOPIRAMATE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for Topiramate from Zydus Lifesciences Limited, granting approval for a generic version of the anti-…
-
FDA approval · 2024-09-09FDA Approved: GABAPENTIN — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for gabapentin from Rising Pharma Holdings, Inc. The approval indicates a modification to the dr…
-
FDA approval · 2024-09-04FDA Approved: LACOSAMIDE — Original Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approves Unichem Pharmaceuticals' original application for lacosamide, enabling a generic version of the seizure medication. The approva…
-
CLINICAL_TRIALS research · 2024-08-30Clinical Trial Update: Epilepsy Learning Healthcare System (ELHS)
A study update for the Epilepsy Learning Healthcare System (ELHS) sponsored by the Epilepsy Foundation of America, currently recruiting to i…
-
CLINICAL_TRIALS withdrawal · 2024-08-30Clinical Trial Update: Epilepsy Self-Management for Spanish Speakers: HOBSCOTCH - ESPANOL [NA]
The clinical trial HOBSCOTCH - ESPANOL for epilepsy self-management in Spanish speakers has been withdrawn.
-
FDA approval · 2024-08-29FDA Approved: LEVETIRACETAM — Supplemental Application (Solco healthcare U.S., LLC)
The FDA approved a supplemental application for a generic levetiracetam formulation developed by Solco Healthcare U.S., LLC.
-
CLINICAL_TRIALS trial_result · 2024-08-28Clinical Trial Update: Optimization of VNS in Epileptic Patients to Induce Cardioprotection [NA]
Clinical trial results are reported for optimizing vagus nerve stimulation (VNS) in epileptic patients to induce cardioprotection. The study…
-
FDA approval · 2024-08-28FDA Approved: LEVETIRACETAM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for a generic levetiracetam product from Aurobindo Pharma Limited.
-
CLINICAL_TRIALS research · 2024-08-27Clinical Trial Update: Neuroliten MVP System Clinical Observation Study
Clinical trial update: The Neuroliten MVP System Clinical Observation Study sponsored by Enliten AI is currently active but not recruiting f…
-
CLINICAL_TRIALS research · 2024-08-27Clinical Trial Update: Impact of Capturing Ictal Events With Ultra-long-term Ambulatory EEG Monitoring With Remote EEG Monitoring System. [NA]
Clinical trial update on NCT06027749 evaluating ultra-long-term ambulatory EEG monitoring with a remote EEG system to capture ictal events i…
-
FDA approval · 2024-08-26FDA Approved: LEVETIRACETAM ER — Supplemental Application (Westminster Pharmaceuticals, LLC)
The FDA approved Westminster Pharmaceuticals' supplemental application to authorize the levetiracetam extended-release formulation (LEVETIRA…
-
CLINICAL_TRIALS trial_result · 2024-08-23Clinical Trial Update: XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy [Phase 3]
Phase 3 trial of XEN496 (ezogabine) in children with KCNQ2 developmental and epileptic encephalopathy was terminated with results posted.
-
CLINICAL_TRIALS research · 2024-08-23Clinical Trial Update: Assessment of Adults Epidemiological Characteristics of Status Epilepticus in the French West Indies and in French Guiana
This clinical trial update outlines an epidemiological assessment of adults with Status Epilepticus in the French West Indies and in French …